Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Beiersdorf sales

Executive Summary

Cosmed division revenues increased 7.2% to $699.3 mil. (€1=$.89) in first quarter, Beiersdorf announces in 1financial presentation April 23. Sales for the division, which includes the Nivea, La Prairie and Juvena brands, dropped 5.5% to $190.4 mil. in the Americas region, but experienced double-digit growth in Europe, excluding Germany, and in Africa, Asia and Australia, company says. Consolidated Q1 sales were $1.06 bil., up 3.6% from the prior-year period, which included sales from company's advanced wound care business, divested in the first quarter 2001. Cosmed division sales for the year will increase 8%, earnings before interest and taxes will advance 12%, Beiersdorf predicts. Company also reported full-year results on target with preliminary figures released in February (2"The Rose Sheet" Feb. 25, 2002, p. 3)...
Advertisement

Related Content

Juvena Ulti-Max Face To Debut As Q10 Extension
Juvena Ulti-Max Face To Debut As Q10 Extension
Advertisement
UsernamePublicRestriction

Register

RS010234

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel